All In Biotech

Drug Trial Radar · NCT00144339

Evaluation of the Long- Term Effects of Spiriva on Lung Function in COPD Patients

A Randomized, Double-blind, Placebo-controlled, Parallel Group Trial Assessing the Rate of Decline of Lung Function With Tiotropium 18 mcg Inhalation Capsule Once Daily in Patients With Chronic Obstructive Pulmonary Disease (COPD).

Last checked: Nov 20, 2026Latest source record: May 20, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,993

Actual

Start

Dec 2002

Primary completion

Feb 2008

Sponsor

Lead sponsor
Boehringer IngelheimBoehringer Ingelheim
Sponsor type
Industry
First posted
Sep 5, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Model
Parallel
Primary purpose
Treatment
Who can join
All sexes, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this trial is to determine whether daily treatment with tiotropium (Spiriva®, Bromuro de Tiotropio®) inhalation capsule via HandiHaler® reduces the rate of decline in lung function over time in patients with COPD.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

  • tiotropiumDrug

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Pre-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 YearsTime frame: From day 30 to 4 years
  2. Post-bronchodilator Forced Expiratory Volume in One Second (FEV1) Rate of Decline From Day 30 to 4 YearsTime frame: From day 30 to 4 years

Locations

490 sites in 37 countries. Site status is shown where the registry gives one.

  • 205.235.3779 Boehringer Ingelheim Investigational Site

    Anniston, Alabama

  • 205.235.3785 Boehringer Ingelheim Investigational Site

    Birmingham, Alabama

  • 205.235.3804 Boehringer Ingelheim Investigational Site

    Jasper, Alabama

  • 205.235.3795 Boehringer Ingelheim Investigational Site

    Mobile, Alabama

  • 205.235.3759 Boehringer Ingelheim Investigational Site

    Phoenix, Arizona

  • 205.235.3770 Boehringer Ingelheim Investigational Site

    Carmichael, California

  • 205.235.3778 Boehringer Ingelheim Investigational Site

    Escondito, California

  • 205.235.3810 Boehringer Ingelheim Investigational Site

    Lakewood, California

  • 205.235.3758 Boehringer Ingelheim Investigational Site

    Long Beach, California

  • 205.235.3812 Boehringer Ingelheim Investigational Site

    Long Beach, California

  • 205.235.3773 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 205.235.3800 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 205.235.3802 Boehringer Ingelheim Investigational Site

    Los Angeles, California

  • 205.235.3786 Pulmonary and Critical Care Medicine

    Orange, California

  • 205.235.3811 Boehringer Ingelheim Investigational Site

    Palo Alto, California

  • 205.235.3741 Boehringer Ingelheim Investigational Site

    Rancho Mirage, California

  • 205.235.3717 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 205.235.3781 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 205.235.3784 Boehringer Ingelheim Investigational Site

    San Diego, California

  • 205.235.3760 Boehringer Ingelheim Investigational Site

    Sepulveda, California

  • 205.235.3711 Boehringer Ingelheim Investigational Site

    Stockton, California

  • 205.235.3764 Boehringer Ingelheim Investigational Site

    Denver, Colorado

  • 205.235.3783 Boehringer Ingelheim Investigational Site

    Wheat Ridge, Colorado

  • 205.235.3727 Boehringer Ingelheim Investigational Site

    Hartford, Connecticut

  • 205.235.3808 Boehringer Ingelheim Investigational Site

    Hartford, Connecticut

  • 205.235.3793 Boehringer Ingelheim Investigational Site

    Norwalk, Connecticut

  • 205.235.3815 Boehringer Ingelheim Investigational Site

    West Haven, Connecticut

  • 205.235.3706 Boehringer Ingelheim Investigational Site

    Bay Pines, Florida

  • 205.235.3762 Boehringer Ingelheim Investigational Site

    Brandon, Florida

  • 205.235.3707 Boehringer Ingelheim Investigational Site

    Largo, Florida

  • 205.235.3703 Boehringer Ingelheim Investigational Site

    Melbourne, Florida

  • 205.235.3775 Boehringer Ingelheim Investigational Site

    Panama City, Florida

  • 205.235.3743 Boehringer Ingelheim Investigational Site

    Sarasota, Florida

  • 205.235.3756 Boehringer Ingelheim Investigational Site

    Tampa, Florida

  • 205.235.3739 Boehringer Ingelheim Investigational Site

    West Palm Beach, Florida

  • 205.235.3719 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 205.235.3790 Boehringer Ingelheim Investigational Site

    Atlanta, Georgia

  • 205.235.3716 Boehringer Ingelheim Investigational Site

    Augusta, Georgia

  • 205.235.3794 Boehringer Ingelheim Investigational Site

    Stockbridge, Georgia

  • 205.235.3724 Boehringer Ingelheim Investigational Site

    Coeur d'Alene, Idaho

Showing 40 of 490 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.